search
Back to results

Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088

Primary Purpose

Autoimmune Haemolytic Anaemia

Status
Active
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
SAR445088
Sponsored by
Bioverativ, a Sanofi company
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Autoimmune Haemolytic Anaemia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria :

Male and female adult patients ≥18 years of age with CAD who:

  • met the eligibility criteria of a previous study evaluating BIVV020;
  • successfully enrolled and completed dosing in a previous study evaluating BIVV020;
  • successfully completed end of study procedures in a previous study evaluating BIVV020; and
  • per Investigator judgement, had a favorable benefit to risk profile after receiving BIVV020.

Documented vaccinations against encapsulated bacterial pathogens given within five years of enrollment and at least 14 days prior to dosing.

Having given written informed consent prior to undertaking any study-related procedure.

Exclusion criteria:

Cold agglutinin syndrome secondary to infection, rheumatologic disease, or known high grade hematologic malignancy, or known solid organ tumor.

Clinically relevant infection within one month of enrollment.

Treatment with anti-CD20 monotherapy within three months or anti CD20 combination therapies within six months prior to screening.

Concurrent treatment with systemic immunosuppressive agents targeting B- or T-cell function and/or cytotoxic agents within 3 months prior to screening. Concurrent treatment with other systemic immunosuppressants within 5.5 half-lives of the drug prior to screening.

Any specific complement system inhibitor other than BIVV020 (eg, eculizumab) within three months prior to screening.

Concurrent treatment with systemic corticosteroids other than a stable daily dose equivalent to ≤10 mg/day prednisone within three months prior to screening.

History of hypersensitivity to BIVV020 or any of its components.

If female, pregnant or lactating

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Sites / Locations

  • Investigational Site Number :2760001
  • Investigational Site Number :3800001
  • Investigational Site Number :5280001
  • Investigational Site Number :5780001
  • Investigational Site Number :8260001

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

SAR445088

Arm Description

Repeat dose of SAR445088

Outcomes

Primary Outcome Measures

Number of participants with treatment-emergent adverse events (TEAE)
The number of participants experiencing TEAEs will be reported for the overall safety population.

Secondary Outcome Measures

Mean change from baseline in total bilirubin over time
Assessment of total bilirubin
Mean change from baseline in hemoglobin over time
Assessment of hemoglobin
Mean change from baseline in lactate dehydrogenase over time
Assessment of lactate dehydrogenase
Mean change from baseline in reticulocyte count over time
Assessment of reticulocyte count
Complement System Classical Pathway Levels as Measured by WIESLAB Assay
Inhibition by SAR445088 of the complement system classical pathway measured by the WIESLAB assay.
Complement System Alternative Pathway Levels as Measured by WIESLAB Assay
Part 1: Effect of SAR445088 on the complement system alternative pathway measured by the WIESLAB assay.
Mean change in CH50 over time
Complement CH50 is a blood test that helps us determine whether protein abnormalities and deficiencies in the complement system are responsible for any increase in autoimmune activity. It will be assessed using complement assays.
Total Complement Factor C4 Levels
Total C4 Levels will be assessed in plasma using complement assays
PK parameter: Cmax
Maximum observed concentration (Cmax) of SAR445088 in plasma will be assessed
PK Parameter: AUC
Area under the plasma concentration versus time curve calculated using the trapezoidal method at steady state
Number of participants with anti-SAR445088 antibodies
The immunogenicity for SAR445088 will be assessed by summarizing the number of participants with anti-SAR445088 antibodies (ADA)

Full Information

First Posted
March 15, 2021
Last Updated
August 22, 2023
Sponsor
Bioverativ, a Sanofi company
search

1. Study Identification

Unique Protocol Identification Number
NCT04802057
Brief Title
Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088
Official Title
An Open-label, Long-term, Safety and Tolerability Study of SAR445088 in Participants With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
March 22, 2021 (Actual)
Primary Completion Date
June 16, 2028 (Anticipated)
Study Completion Date
June 16, 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bioverativ, a Sanofi company

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
Primary Objective: To assess the long-term safety and tolerability in patients with cold agglutinin disease (CAD), after multiple doses of SAR445088 Secondary Objective: To assess, in patients with cold agglutinin disease (CAD), after multiple doses of SAR445088: The long-term effect of SAR445088 on complement mediated hemolysis The long-term pharmacodynamics (PD) effect of SAR445088 relating to complement inhibition The long-term pharmacokinetic (PK) profile of SAR445088 The long-term immunogenicity of SAR445088
Detailed Description
The screening period for this study is up to 6 weeks. The treatment period for this study will continue for 2 years after last participant entered Part 2 (either having switched from Part 1 or as a SAR445088-naïve participant), or until SAR445088 development is discontinued, whichever comes first.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Autoimmune Haemolytic Anaemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
9 (Actual)

8. Arms, Groups, and Interventions

Arm Title
SAR445088
Arm Type
Experimental
Arm Description
Repeat dose of SAR445088
Intervention Type
Drug
Intervention Name(s)
SAR445088
Intervention Description
Pharmaceutical form: solution for injection Route of administration: IV and SC (Part 1) IV (Part 2)
Primary Outcome Measure Information:
Title
Number of participants with treatment-emergent adverse events (TEAE)
Description
The number of participants experiencing TEAEs will be reported for the overall safety population.
Time Frame
Day 1 or Day 1-IV to end of study, approximately 6 years
Secondary Outcome Measure Information:
Title
Mean change from baseline in total bilirubin over time
Description
Assessment of total bilirubin
Time Frame
Day 1 or Day 1-IV to end of study, approximately 6 years
Title
Mean change from baseline in hemoglobin over time
Description
Assessment of hemoglobin
Time Frame
Day 1 or Day 1-IV to end of study, approximately 6 years
Title
Mean change from baseline in lactate dehydrogenase over time
Description
Assessment of lactate dehydrogenase
Time Frame
Day 1 or Day 1-IV to end of study, approximately 6 years
Title
Mean change from baseline in reticulocyte count over time
Description
Assessment of reticulocyte count
Time Frame
Day 1 or Day 1-IV to end of study, approximately 6 years
Title
Complement System Classical Pathway Levels as Measured by WIESLAB Assay
Description
Inhibition by SAR445088 of the complement system classical pathway measured by the WIESLAB assay.
Time Frame
Day 1 or Day 1-IV to Week 48-IV
Title
Complement System Alternative Pathway Levels as Measured by WIESLAB Assay
Description
Part 1: Effect of SAR445088 on the complement system alternative pathway measured by the WIESLAB assay.
Time Frame
Day 1 to Week 24
Title
Mean change in CH50 over time
Description
Complement CH50 is a blood test that helps us determine whether protein abnormalities and deficiencies in the complement system are responsible for any increase in autoimmune activity. It will be assessed using complement assays.
Time Frame
Day 1 or Day 1-IV to end of study, approximately 6 years
Title
Total Complement Factor C4 Levels
Description
Total C4 Levels will be assessed in plasma using complement assays
Time Frame
Day 1 or Day 1-IV to end of study, approximately 6 years
Title
PK parameter: Cmax
Description
Maximum observed concentration (Cmax) of SAR445088 in plasma will be assessed
Time Frame
Day 1 or Day 1-IV to Week 48-IV
Title
PK Parameter: AUC
Description
Area under the plasma concentration versus time curve calculated using the trapezoidal method at steady state
Time Frame
Day 1 or Day 1-IV to Week 48-IV
Title
Number of participants with anti-SAR445088 antibodies
Description
The immunogenicity for SAR445088 will be assessed by summarizing the number of participants with anti-SAR445088 antibodies (ADA)
Time Frame
Day 1 or Day 1-IV to end of study, approximately 6 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female adult patients ≥18 years of age with CAD who were previously treated with SAR445088 and met criteria the below criteria for entry into Part 1: met the eligibility criteria of a previous study evaluating SAR445088; successfully enrolled and completed dosing in a previous study evaluating SAR445088; successfully completed end of study procedures in a previous study evaluating SAR445088; and per Investigator judgement, had a favorable benefit-to-risk profile after receiving SAR445088. OR were never treated with SAR445088 before entering Part 2, and met the below criteria to establish CAD diagnosis: chronic hemolysis; polyspecific direct antiglobulin test (DAT) positive status; monospecific DAT strongly positive for C3d; cold agglutinin [CAg] titer ≥64 at 4°C; IgG DAT ≤1+; hemoglobin level ≤10 g/dL; elevated bilirubin not attributable to liver disease; Documented vaccinations against encapsulated bacterial pathogens given within five years of enrollment and at least 14 days prior to dosing (vaccinations have to be initiated at least 14 days prior to dosing and completed before Week 5 of Part 2). Contraception (with double contraception methods) for male and female participants; not pregnant or breastfeeding for female participants; no sperm donation for male participants. Having given written informed consent prior to undertaking any study-related procedure. Exclusion Criteria: Cold agglutinin syndrome secondary to infection, rheumatologic disease, or known high-grade hematologic malignancy, or known solid organ tumor. Clinically relevant infection within 1 month of enrollment. Clinical diagnosis of systemic lupus erythematosus (SLE). Treatment with anti-CD20 monotherapy within 3 months or anti-CD20 combination therapies within 6 months prior to screening. Concurrent treatment with systemic immunosuppressive agents targeting B- or T-cell function and/or cytotoxic agents within 3 months prior to screening. Concurrent treatment with other systemic immunosuppressants within 5.5 half-lives of the drug prior to screening. Any specific complement system inhibitor other than SAR445088 (eg, eculizumab) within 3 months prior to screening. Concurrent treatment with systemic corticosteroids other than a stable daily dose equivalent to ≤10 mg/day prednisone within 3 months prior to screening. History of hypersensitivity to SAR445088 or any of its components. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Sciences & Operations
Organizational Affiliation
Sanofi
Official's Role
Study Director
Facility Information:
Facility Name
Investigational Site Number :2760001
City
Essen
ZIP/Postal Code
45147
Country
Germany
Facility Name
Investigational Site Number :3800001
City
Milano
ZIP/Postal Code
20122
Country
Italy
Facility Name
Investigational Site Number :5280001
City
Amsterdam
ZIP/Postal Code
1105AZ
Country
Netherlands
Facility Name
Investigational Site Number :5780001
City
Bergen
ZIP/Postal Code
5021
Country
Norway
Facility Name
Investigational Site Number :8260001
City
London
State/Province
London, City Of
ZIP/Postal Code
NW1 2PG
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Learn more about this trial

Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088

We'll reach out to this number within 24 hrs